drugset / Trial / NCT06456138
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Phase 1/2
Not yet recruiting
60 enrolled
Shanghai Chest Hospital
BeiGene · collabChia Tai Tianqing Pharmaceutical Group Co., Ltd. · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. KRAS-mutant NSCLC had been considered undruggable in past decades. This research sought to address a significant challenge in treating NSCLC with KRAS mutations, which are notoriously difficult to target effectively. Here, we proposal that the combined use of anlotinib and trametinib combined with tislelizumab may form an effective strategy for the treatment of KRAS-mutant NSCLC patients.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-06-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 6 mg | Oral |
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Trametinib | Small molecule | 1 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |